Paul Elliot Mann, who serves as Executive Chairman of ASP Isotopes Inc. (NASDAQ:ASPI), sold 162,153 shares of the companys common stock on March 2, 2026. The block traded at an average price of $5.436 per share, producing gross proceeds of $881,463.
The sales execution showed intraday price variation, with individual trades in the sequence ranging from $5.10 to $5.57 per share. After the disposition, Mann retained direct ownership of 7,597,385 shares of ASP Isotopes common stock.
The filing accompanying the transaction states the sale was carried out under a pre-arranged Rule 10b5-1 trading plan. The company disclosed the purpose of the disposition was to satisfy tax obligations tied to the vesting of a restricted stock award.
Market context for the trade: ASP Isotopes shares have been trading materially below their 52-week high of $14.49 and the stock has declined by just over 31 percent in the last six months. Analysis from InvestingPro cited in company disclosures indicates ASPI currently appears overvalued relative to its Fair Value and exhibits high volatility. The InvestingPro note also references additional ProTips and more comprehensive analysis available to subscribers.
Corporate strategy and regulatory developments have continued in parallel with the insider transaction. ASP Isotopes recently completed its acquisition of Renergen Limited, an integration intended to combine ASPs enrichment technologies with Renergens South African operations. Company statements identify targeted end markets for the combined capabilities as including semiconductor manufacturing and clean energy applications.
The South African Takeover Regulation Panel has approved the acquisition, clearing the way for the planned scheme of arrangement to proceed, according to company announcements. Separately, Cantor Fitzgerald reiterated an Overweight rating on ASP Isotopes, citing the companys isotope-enrichment technology.
On the governance front, shareholders at the annual meeting elected two Class III directors, Sipho N. Maseko and Todd Wider, M.D., with both to serve until the 2028 annual meeting. In addition, the companys subsidiary Quantum Leap Energy has established a Strategic Advisory Board composed of experts from the nuclear fuel and advanced materials sectors.
Taken together, the recent insider sale, the acquisition close and the governance moves reflect a phase of corporate transition for ASP Isotopes. The sale itself was executed under a planned trading schedule to address tax liabilities associated with equity vesting, while the company continues to pursue strategic initiatives intended to expand its technological and market footprint.